RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	6.53	6.53	61.8	85.76	64.36	6.29
Revenue Growth (YoY)	-90.81%	-89.43%	-27.94%	33.25%	923.03%	-24.75%
Cost of Revenue	3.46	3.46	33.34	49.41	0	2.26
Gross Profit	3.07	3.07	28.46	36.35	64.36	4.03
Selling, General & Admin	30.98	30.98	64.03	87.99	25.38	29.81
Research & Development	3.53	3.53	7.28	29.5	0	17.42
Other Operating Expenses	-44.06	-44.06	0	0	0	0
Operating Expenses	-9.56	-9.56	71.31	117.49	25.38	47.23
Operating Income	12.63	12.63	-42.84	-81.14	38.98	-43.2
Interest Expense / Income	-11.28	-11.28	28.83	16.61	12.49	-0.9
Other Expense / Income	-	-	-	-	102.67	-
Pretax Income	23.92	23.92	-71.67	-97.74	-76.17	-42.3
Net Income	23.92	23.92	-71.67	-97.74	-76.17	-42.3
Shares Outstanding (Basic)	1,278	1,278	638	468	353	284
Shares Change	100.19%	100.19%	36.43%	32.67%	24.33%	33.36%
EPS (Basic)	4.00	4.00	-48.00	-84.00	-84.00	-56.00
EPS (Diluted)	4.00	4.00	-48.00	-84.00	-84.00	-56.00
Free Cash Flow	-35.83	-35.83	-29.38	-65.16	-48.99	-40.92
Free Cash Flow Per Share	-11.21	-11.21	-18.41	-55.70	-55.55	-57.69
Gross Margin	47.03%	47.03%	46.06%	42.39%	100.00%	64.09%
Operating Margin	193.45%	193.45%	-69.33%	-94.61%	60.57%	-686.71%
Profit Margin	366.25%	366.25%	-115.97%	-113.98%	-118.36%	-672.45%
Free Cash Flow Margin	-548.71%	-548.71%	-47.55%	-75.98%	-76.11%	-650.41%
EBITDA	14.62	14.62	-34.69	-62.99	-54.94	-41.99
EBITDA Margin	223.92%	223.92%	-56.13%	-73.45%	-85.36%	-667.43%
Depreciation & Amortization	1.99	1.99	8.15	18.15	8.75	1.21
EBIT	12.63	12.63	-42.84	-81.14	-63.68	-43.2
EBIT Margin	193.45%	193.45%	-69.33%	-94.61%	-98.95%	-686.71%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).